Affymetrix, Inc. (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry. The eBioscience segment primarily focuses on the development, manufacture, marketing and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. It maintains sales and distribution operations across the United States, Europe, Latin America and Asia.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Diagnostics & Testing
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NASDAQ:AFFX
- CUSIP: 00826T10
- Web: www.affymetrix.com
- 50 Day Moving Avg: $14.15
- 200 Day Moving Avg: $11.20
- 52 Week Range: $8.28 - $16.15
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 32.58
- P/E Growth: 0.00
- Net Margins: 4.24%
- Return on Equity: 4.84%
- Return on Assets: 2.97%
- Average Volume: 3.49 million shs.
Frequently Asked Questions for Affymetrix (NASDAQ:AFFX)
What is Affymetrix's stock symbol?
Affymetrix trades on the NASDAQ under the ticker symbol "AFFX."
How were Affymetrix's earnings last quarter?
Affymetrix, Inc. (NASDAQ:AFFX) issued its quarterly earnings data on Wednesday, February, 17th. The company reported $0.09 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.11 by $0.02. The business had revenue of $95.60 million for the quarter, compared to analysts' expectations of $93.29 million. Affymetrix had a return on equity of 4.84% and a net margin of 4.24%. During the same period in the previous year, the firm posted $0.09 EPS. View Affymetrix's Earnings History.
Who are some of Affymetrix's key competitors?
Some companies that are related to Affymetrix include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), Valeant Pharmaceuticals Intl (VRX), NMC Health PLC (NMC), ConvaTec Group PLC (CTEC), Health Net (HNT), Catalent (CTLT), Patheon NV (PTHN), Mediclinic International PLC (MDC), Puma Biotechnology (PBYI), Cotiviti Holdings (COTV), WuXi PharmaTech (Cayman) (WX) and Enerplus Corp (ERF).
How do I buy Affymetrix stock?
Shares of Affymetrix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Affymetrix's stock price today?
MarketBeat Community Rating for Affymetrix (NASDAQ AFFX)MarketBeat's community ratings are surveys of what our community members think about Affymetrix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Affymetrix stock can currently be purchased for approximately $14.01.
Earnings History for Affymetrix (NASDAQ:AFFX)Earnings History by Quarter for Affymetrix (NASDAQ AFFX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/17/2016||Q415||$0.11||$0.09||$93.29 million||$95.60 million||View||N/A|
|10/28/2015||Q315||$0.08||$0.10||$88.04 million||$86.50 million||View||Listen|
|7/29/2015||Q215||$0.07||$0.12||$88.61 million||$89.00 million||View||Listen|
|4/29/2015||Q115||$0.04||$0.10||$87.30 million||$88.70 million||View||Listen|
|2/4/2015||Q414||$0.07||$0.09||$91.80 million||$93.50 million||View||Listen|
|10/30/2014||Q314||$0.04||$0.08||$84.40 million||$87.10 million||View||Listen|
|7/31/2014||Q214||$0.03||$0.07||$83.30 million||$85.40 million||View||Listen|
|5/1/2014||Q114||$0.02||$0.03||$81.10 million||$83.00 million||View||Listen|
|2/5/2014||Q413||$0.07||$0.02||$89.98 million||$92.60 million||View||Listen|
|7/31/2013||Q2 2013||($0.01)||$0.04||$78.53 million||$79.46 million||View||Listen|
|4/30/2013||Q1 2013||($0.02)||($0.01)||$78.04 million||$77.90 million||View||Listen|
|1/31/2013||Q4 2012||($0.03)||($0.02)||$84.06 million||$84.40 million||View||Listen|
|11/5/2012||Q312||($0.03)||($0.03)||$84.56 million||$79.60 million||View||N/A|
Earnings Estimates for Affymetrix (NASDAQ:AFFX)
Current Year EPS Consensus Estimate: $0.39 EPS
Next Year EPS Consensus Estimate: $0.43 EPS
Dividend History for Affymetrix (NASDAQ:AFFX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Affymetrix (NASDAQ:AFFX)Insider Trades by Quarter for Affymetrix (NASDAQ:AFFX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/15/2015||Robert H Trice||Director||Sell||2,500||$9.40||$23,500.00|| |
|11/17/2015||Robert H Trice||Director||Sell||2,500||$9.00||$22,500.00|| |
|10/15/2015||Robert H Trice||Director||Sell||2,500||$9.00||$22,500.00|| |
|7/20/2015||Frank Witney||CEO||Sell||37,991||$11.20||$425,499.20|| |
|7/10/2015||Frank Witney||CEO||Sell||62,756||$11.00||$690,316.00|| |
|6/26/2015||Frank Witney||CEO||Sell||75,000||$11.22||$841,500.00|| |
|6/22/2015||David A Weber||EVP||Sell||33,879||$12.00||$406,548.00|| |
|6/19/2015||David A Weber||EVP||Sell||14,760||$12.00||$177,120.00|| |
|6/4/2015||Frank Witney||CEO||Sell||75,000||$11.78||$883,500.00|| |
|2/17/2015||Gavin Wood||CFO||Sell||1,300||$11.40||$14,820.00|| |
|1/20/2015||Gavin Wood||CFO||Sell||22,500||$11.77||$264,825.00|| |
|1/12/2015||Gavin Wood||CFO||Sell||10,200||$10.77||$109,854.00|| |
|12/29/2014||Gavin Wood||CFO||Sell||18,734||$10.20||$191,086.80|| |
|11/19/2013||Robert Trice||Director||Sell||6,205||$7.98||$49,515.90|| |
|8/21/2012||Timothy C Barabe||CFO||Buy||10,000||$3.75||$37,500.00|| |
|8/17/2012||Timothy C Barabe||CFO||Buy||5,550||$3.99||$22,144.50|| |
|8/13/2012||Timothy C Barabe||CFO||Buy||4,450||$3.99||$17,755.50|| |
Headline Trends for Affymetrix (NASDAQ:AFFX)
Latest Headlines for Affymetrix (NASDAQ:AFFX)
Affymetrix (AFFX) Chart for Saturday, September, 23, 2017